Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
- Evaluated articles (Rapid Reviews Infectious Diseases)
Abstract
Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.
Article activity feed
-
-
Rachel Palinski
Review 2: "A live attenuated vaccine offers superior mucosal and systemic immunity to SARS-CoV-2"
This preprint reports improved immune responses to and efficacy of a live attenuated SARS-CoV-2 vaccine, compared to Pfizer mRNA vaccine, and an adenovirus-vectored spike protein vaccine (Ad2) in hamsters. Reviewers find the study significant, with the data presented as reliable.
-
Qiuhong Wang, Mingde Liu
Review 1: "A live attenuated vaccine offers superior mucosal and systemic immunity to SARS-CoV-2"
This preprint reports improved immune responses to and efficacy of a live attenuated SARS-CoV-2 vaccine, compared to Pfizer mRNA vaccine, and an adenovirus-vectored spike protein vaccine (Ad2) in hamsters. Reviewers find the study significant, with the data presented as reliable.
-
Strength of evidence
Reviewers: Qiuhong Wang, Mingde Liu (Ohio State University) | 📘📘📘📘📘
Rachel Palinski (Kansas State University) | 📗📗📗📗◻️ -
SciScore for 10.1101/2022.05.16.492138: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: All animal experiments were performed in compliance with relevant institutional, national, and international guidelines for care and humane use of animal and approved by the Landesamt für Gesundheit und Soziales in Berlin, Germany (permit number 0086/20). Sex as a biological variable Hamsters were randomly assigned into groups, with 50 – 60 % of the animals in each group being female. Randomization Hamsters were randomly assigned into groups, with 50 – 60 % of the animals in each group being female. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Antigen retrieval was performed using microwave … SciScore for 10.1101/2022.05.16.492138: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: All animal experiments were performed in compliance with relevant institutional, national, and international guidelines for care and humane use of animal and approved by the Landesamt für Gesundheit und Soziales in Berlin, Germany (permit number 0086/20). Sex as a biological variable Hamsters were randomly assigned into groups, with 50 – 60 % of the animals in each group being female. Randomization Hamsters were randomly assigned into groups, with 50 – 60 % of the animals in each group being female. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Antigen retrieval was performed using microwave heating (600 W) in 10 mM citric acid (pH 6.0) for 12 min for SARS-CoV-1 nucleoprotein antibody (Sino Biological Inc.; Beijing, China) and using recombinant protease from Streptomyces griseus (PanReac Applichem, Darmstadt, Germany) for 13 min at 37°C for IgA antibody. SARS-CoV-1 nucleoproteinsuggested: NoneIgAsuggested: NoneAnti-SARS-CoV-1 NP mouse monoclonal antibody (Sino Biological Inc.; Beijing, China, dilution: 1:500) and rabbit anti hamster IgA antibody (Brookwood Biomedical, Jemison, AL, dilution: 1:250) were incubated at 4°C overnight followed by washing and incubation with a secondary biotinylated goat anti-mouse IgG antibody (dilution: 1:200, Vector Laboratories, Burlingame, California, USA). Anti-SARS-CoV-1 NPsuggested: Noneanti hamster IgAsuggested: Noneanti-mouse IgGsuggested: NoneThe plates were covered and incubated for 2 h at room temperature before the washing step was repeated and 50 μL of secondary antibody (Brookwood biomedical, Rabbit Anti-Hamster IgA, HRP-conjugated) diluted 1:1000 was applied per well. Anti-Hamster IgAsuggested: NoneDay 0 samples of the prime-boost trial could not be tested for neutralizing antibodies against B.1.351 (Beta) due to lack of material. B.1.351suggested: NoneExperimental Models: Cell Lines Sentences Resources In addition, the cell culture medium for Vero-TMPRSS2 cells contained 1000 μg/mL geneticin (G418) to ensure selection for cells expressing the genes for neomycin resistance and TMPRSS2. Vero-TMPRSS2suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48), Beta – B.1.351 (hCoV-19/Netherlands/NoordHolland_20159/2021), and Delta – B.1.617.2 (SARS-CoV-2, Human, 2021, Germany ex India, 20A/452R (B.1.617) were propagated on VeroE6-TMPRSS2 cells. VeroE6-TMPRSS2suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Omicron BA.1 - B.1.1.529.1 (hCoV-19/Germany/BE-ChVir26335/2021, EPI_ISL_7019047) was propagated on CaLu-3 cells. CaLu-3suggested: KCLB Cat# 30055, RRID:CVCL_0609)Mock-vaccinated hamsters were vaccinated by intranasal instillation with sterile cell culture supernatant obtained from uninfected VeroE6-TMPRSS cells. VeroE6-TMPRSSsuggested: NoneVaccine preparations: sCPD9 was grown on Vero-TMRSS cells and titrated on Vero E6 cells as described previously, final titers were adjusted to 2 × 106 FFU/mL in MEM. Vero-TMRSSsuggested: NoneVero E6suggested: NoneExperimental Models: Organisms/Strains Sentences Resources Cell isolation from blood and lungs: White blood cells were isolated from EDTA-blood as previously described, steps included erylysis and cell filtration prior counting. lungs: Whitesuggested: NoneSoftware and Algorithms Sentences Resources Mesocricetus auratus genome annotation: For quantification of gene expression, we used the MesAur 2.0 genome assembly and annotation available via the NCBI genome database (https://www.ncbi.nlm.nih.gov/genome/11998?genome_assembly_id=1585474). MesAursuggested: NoneResults from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our single-cell RNA-sequencing analysis has several limitations. This technique, as employed here, cannot fully capture processes such as reactivation of memory cells due to lack of surface markers and cell type-specific enrichment. Due to incomplete annotation of the Syrian hamster genome, we were not able to identify IgA-positive cells. Data quality of nasal mucosa cells was comparatively low due to the difficult dissociation of the tissue, which limits our observations at the site of initial infection. An important and frequently discussed issue with live attenuated vaccines is their potential susceptibility to previously established immunity (69), which would restrict vaccine virus replication and potentially limit their use as booster vaccines after initial immunization by vaccination or natural infection. Our results indicate however, that sCPD9 does effectively boost immune responses and greatly improves protection when applied three weeks after initial mRNA vaccination. Importantly, sCPD9 enhances humoral immune responses, especially against known immune escape variants such as Beta and Omicron BA.1, while also improving the virological outcome of a heterologous challenge infection when applied as a booster three weeks after initial vaccination. This indicates a wide scope for the use of live attenuated vaccines in populations that exhibit an already high degree of baseline immunity induced by previous vaccination or infection; a situation clearly present in many part...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
